ArticleAntibiotics (Basel, Switzerland)2023
Carbapenemase-Producing
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Molecular Characterisation and Descriptive Analysis of Carbapenemase-Producing Enterobacterales: Striking Epidemiological Changes.Antibiotics (Basel, Switzerland) · 2026Article
- Resistance to Plazomicin: An Analysis of the Evidence from In Vitro Antimicrobial Susceptibility Studies.Antibiotics (Basel, Switzerland) · 2026Review
- Genomic Characterization of NDM-1 Harboring Extensively-Drug ResistanceJournal of tropical medicine · 2025Article
- Characterizing carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Prevalence of extended-spectrum β-lactamase and carbapenem-resistantSaudi medical journal · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
During the COVID-19 pandemic, intensive care units (ICUs) operated at or above capacity, and the number of ICU patients coinfected by nosocomial microorganisms increased. Here, we characterize the population structure and resistance mechanisms of carbapenemase-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.